Bavarian Nordic A/S BAVA

COP: BAVA | ISIN: DK0015998017   2/01/2025
198,90 DKK (+5,04%)
(+5,04%)   2/01/2025

16 december 2024 · Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India · Persbericht

13 december 2024 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

13 december 2024 · New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic · Persbericht

11 december 2024 · Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program · Persbericht

29 november 2024 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

29 november 2024 · Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise · Persbericht

15 november 2024 · Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 · Persbericht

29 oktober 2024 · First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine · Persbericht

26 september 2024 · Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines · Persbericht

26 september 2024 · Bavarian Nordic Upgrades its Financial Guidance for 2024 · Persbericht

24 september 2024 · Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines · Persbericht

19 september 2024 · Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents · Persbericht

18 september 2024 · Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa · Persbericht

13 september 2024 · Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine · Persbericht

12 september 2024 · Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation · Persbericht

6 september 2024 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

5 september 2024 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

5 september 2024 · First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo · Persbericht

5 september 2024 · Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise · Persbericht

27 augustus 2024 · Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore · Persbericht

Mijn selecties